Compounds > flutroline
Page last updated: 2024-11-06

flutroline

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

flutroline: structure given in first source; RN given refers to cpd without isomeric designation [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID51174
CHEMBL ID57241
SCHEMBL ID121860
MeSH IDM0086421

Synonyms (33)

Synonym
D02662
70801-02-4
flutroline (usan/inn)
cp-36584
flutroline
CHEMBL57241
cp-36,584
4-[8-fluoro-5-(4-fluorophenyl)-3,4-dihydro-1h-pyrido[4,3-b]indol-2-yl]-1-(4-fluorophenyl)butan-1-ol
j922111j7p ,
(+-)-8-fluoro-alpha,5-bis(p-fluorophenyl)-1,3,4,5-tetrahydro-2h-pyrido(4,3-b)indole-2-butanol
cp 36,584
flutroline [usan:inn]
2h-pyrido(4,3-b)indole-2-butanol, 8-fluoro-alpha,5-bis(4-fluorophenyl)-1,3,4,5-tetrahydro-, (+-)-
flutrolino
unii-j922111j7p
flutrolinum
flutrolinum [inn-latin]
flutrolino [inn-spanish]
flutroline [inn]
flutroline [usan]
flutroline [who-dd]
(+/-)-8-fluoro-.alpha.,5-bis(p-fluorophenyl)-1,3,4,5-tetrahydro-2h-pyrido(4,3-b)indole-2-butanol
2h-pyrido(4,3-b)indole-2-butanol, 8-fluoro-.alpha.,5-bis(4-fluorophenyl)-1,3,4,5-tetrahydro-, (+/-)-
SCHEMBL121860
8-fluoro-5-(p-fluorophenyl)-2-[4-(p-fluorophenyl)-4-hydroxybutyl]-2,3,4,5-tetrahydro-1h-pyrido[4,3-b]indole
8-fluoro-5-(p-fluorophenyl)-2-[4-(p-fluoro-phenyl)-4-hydroxybutyl]-2,3,4,5-tetrahydro-1h-pyrido[4,3-b]indole
OYGDOCFZQVGFIP-UHFFFAOYSA-N
4-[8-fluoro-5-(4-fluorophenyl)-1,3,4,5-tetrahydro-2h-pyrido[4,3-b]indol-2-yl]-1-(4-fluorophenyl)-1-butanol
Q27281356
4-[8-fluoro-5-(4-fluorophenyl)-1,3,4,5-tetrahydro-2h-pyrido[4,3-b]indol-2-yl]-1-(4-fluorophenyl)butan-1-ol
DTXSID30867946
2h-pyrido[4,3-b]indole-2-butanol,8-fluoro-a,5-bis(4-fluorophenyl)-1,3,4,5-tetrahydro-
AKOS040751829

Research Excerpts

Bioavailability

ExcerptReferenceRelevance
" The method is linear over the concentration range of 3-60 ng ml-1 and was used to define the drug pharmacokinetics and bioavailability in animals and man."( A gas chromatographic/mass spectrometric assay for flutroline, a gamma-carboline antipsychotic agent, with direct derivatization on a moving needle injector.
Falkner, FC; Fouda, HG; Mullins, FG, 1984)		0.52
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (5)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
DRattus norvegicus (Norway rat)IC50 (µMol)0.01200.00030.50267.7625AID62731
D(3) dopamine receptorRattus norvegicus (Norway rat)IC50 (µMol)0.01200.00030.39075.4000AID62731
D(1B) dopamine receptorRattus norvegicus (Norway rat)IC50 (µMol)0.01200.00030.35635.4000AID62731
D(4) dopamine receptorRattus norvegicus (Norway rat)IC50 (µMol)0.01200.00030.38715.4000AID62731
D(2) dopamine receptorRattus norvegicus (Norway rat)IC50 (µMol)0.01200.00010.54948.4000AID62731
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (16)

Assay IDTitleYearJournalArticle
AID178706Compound was tested for the antagonistic activity against amphetamine-induced stereotypy in rats; (5 mg/kg administered ip 24 hr after the test compound)1986Journal of medicinal chemistry, Jan, Volume: 29, Issue:1
Neuroleptic activity of chiral trans-hexahydro-gamma-carbolines.
AID178843Antipsychotic activity was evaluated by the antagonism of amphetamine in rats when administered subcutaneously after 5 hr1980Journal of medicinal chemistry, Aug, Volume: 23, Issue:8
4a,9b-trans-8-Fluoro-5-(4-fluorophenyl)-2-[4-(4-fluorophenyl)-4-hydroxybutyl]-2,3,4,4a,5,9b-hexahydro-1H-pyrido[4,3-b]indole hydrochloride, a new potent neuroleptic.
AID62883Displacement of [3H]spiroperidol from dopamine receptor of rat corpus striatum homogenate1980Journal of medicinal chemistry, Jun, Volume: 23, Issue:6
Neuroleptic activity in 5-aryltetrahydro-gamma-carbolines.
AID178710Compound was tested for the antagonistic activity against amphetamine-induced stereotypy in rats; (5 mg/kg administered ip 5 hr after the test compound)1986Journal of medicinal chemistry, Jan, Volume: 29, Issue:1
Neuroleptic activity of chiral trans-hexahydro-gamma-carbolines.
AID196427Inhibition of [3H]spiroperidol binding to rat striatal membrane using 0.5 nM ligand.1980Journal of medicinal chemistry, Aug, Volume: 23, Issue:8
4a,9b-trans-8-Fluoro-5-(4-fluorophenyl)-2-[4-(4-fluorophenyl)-4-hydroxybutyl]-2,3,4,4a,5,9b-hexahydro-1H-pyrido[4,3-b]indole hydrochloride, a new potent neuroleptic.
AID178842Antipsychotic activity was evaluated by the antagonism of amphetamine in rats when administered subcutaneously after 24 hr 1980Journal of medicinal chemistry, Aug, Volume: 23, Issue:8
4a,9b-trans-8-Fluoro-5-(4-fluorophenyl)-2-[4-(4-fluorophenyl)-4-hydroxybutyl]-2,3,4,4a,5,9b-hexahydro-1H-pyrido[4,3-b]indole hydrochloride, a new potent neuroleptic.
AID179796Tested for neuroleptic activity by measuring antagonism of d-amphetamine sulfate at intraperitoneal dosage of 5 mg/kg, after 1 hour in rat; Range is 0.1-0.321980Journal of medicinal chemistry, Jun, Volume: 23, Issue:6
Neuroleptic activity in 5-aryltetrahydro-gamma-carbolines.
AID178704Antagonistic activity against amphetamine-induced stereotypy in rats; (5 mg/kg administered ip 1 hr after the test compound).1986Journal of medicinal chemistry, Jan, Volume: 29, Issue:1
Neuroleptic activity of chiral trans-hexahydro-gamma-carbolines.
AID62736Affinity for Dopamine receptors in the rat striatum using [3H]spiroperidol displacement.1986Journal of medicinal chemistry, Oct, Volume: 29, Issue:10
Neuroleptics from the 4a,9b-cis- and 4a,9b-trans-2,3,4,4a,5,9b-hexahydro-1H-pyrido[4,3-b]indole series. 2.
AID176330Inhibition of d-amphetamine induced stereotypy in rats; i.p. treatment 1 hr before amphetamine.1986Journal of medicinal chemistry, Oct, Volume: 29, Issue:10
Neuroleptics from the 4a,9b-cis- and 4a,9b-trans-2,3,4,4a,5,9b-hexahydro-1H-pyrido[4,3-b]indole series. 2.
AID179804Tested for neuroleptic activity by measuring antagonism of d-amphetamine sulfate at intraperitoneal dosage of 5 mg/kg, after 24 hours in rat; Range is 0.32-1.01980Journal of medicinal chemistry, Jun, Volume: 23, Issue:6
Neuroleptic activity in 5-aryltetrahydro-gamma-carbolines.
AID176334Inhibition of d-amphetamine induced stereotypy in rats; i.p. treatment 5 hr before amphetamine.1986Journal of medicinal chemistry, Oct, Volume: 29, Issue:10
Neuroleptics from the 4a,9b-cis- and 4a,9b-trans-2,3,4,4a,5,9b-hexahydro-1H-pyrido[4,3-b]indole series. 2.
AID179812Tested for neuroleptic activity by measuring antagonism of d-amphetamine sulfate at intraperitoneal dosage of 5 mg/kg, after 5 hours in rat; Range is 0.1-0.321980Journal of medicinal chemistry, Jun, Volume: 23, Issue:6
Neuroleptic activity in 5-aryltetrahydro-gamma-carbolines.
AID178844Antipsychotic activity was evaluated by the antagonism of amphetamine in rats when administered subcutaneously after 1 hr1980Journal of medicinal chemistry, Aug, Volume: 23, Issue:8
4a,9b-trans-8-Fluoro-5-(4-fluorophenyl)-2-[4-(4-fluorophenyl)-4-hydroxybutyl]-2,3,4,4a,5,9b-hexahydro-1H-pyrido[4,3-b]indole hydrochloride, a new potent neuroleptic.
AID176332Inhibition of d-amphetamine induced stereotypy in rats; i.p. treatment 24 hr before amphetamine.1986Journal of medicinal chemistry, Oct, Volume: 29, Issue:10
Neuroleptics from the 4a,9b-cis- and 4a,9b-trans-2,3,4,4a,5,9b-hexahydro-1H-pyrido[4,3-b]indole series. 2.
AID62731Inhibition of [3H]spiroperidol (0.5 nM) binding to dopamine receptor from rat striatal membrane.1986Journal of medicinal chemistry, Jan, Volume: 29, Issue:1
Neuroleptic activity of chiral trans-hexahydro-gamma-carbolines.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (9)

TimeframeStudies, This Drug (%)All Drugs %
pre-19908 (88.89)18.7374
1990's1 (11.11)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 11.57

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index11.57 (24.57)
Research Supply Index2.71 (2.92)
Research Growth Index4.28 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (11.57)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials4 (40.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other6 (60.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
chlorpromazine
Chlorpromazine: The prototypical phenothiazine antipsychotic drug. Like the other drugs in this class chlorpromazine's antipsychotic actions are thought to be due to long-term adaptation by the brain to blocking DOPAMINE RECEPTORS. Chlorpromazine has several other actions and therapeutic uses, including as an antiemetic and in the treatment of intractable hiccup.. chlorpromazine : A substituted phenothiazine in which the ring nitrogen at position 10 is attached to C-3 of an N,N-dimethylpropanamine moiety.		2.6530organochlorine compound;
phenothiazines;
tertiary amine		anticoronaviral agent;
antiemetic;
dopaminergic antagonist;
EC 3.4.21.26 (prolyl oligopeptidase) inhibitor;
phenothiazine antipsychotic drug
haloperidol
Haloperidol: A phenyl-piperidinyl-butyrophenone that is used primarily to treat SCHIZOPHRENIA and other PSYCHOSES. It is also used in schizoaffective disorder, DELUSIONAL DISORDERS, ballism, and TOURETTE SYNDROME (a drug of choice) and occasionally as adjunctive therapy in INTELLECTUAL DISABILITY and the chorea of HUNTINGTON DISEASE. It is a potent antiemetic and is used in the treatment of intractable HICCUPS. (From AMA Drug Evaluations Annual, 1994, p279). haloperidol : A compound composed of a central piperidine structure with hydroxy and p-chlorophenyl substituents at position 4 and an N-linked p-fluorobutyrophenone moiety.		4.2641aromatic ketone;
hydroxypiperidine;
monochlorobenzenes;
organofluorine compound;
tertiary alcohol		antidyskinesia agent;
antiemetic;
dopaminergic antagonist;
first generation antipsychotic;
serotonergic antagonist
spiperone
Spiperone: A spiro butyrophenone analog similar to HALOPERIDOL and other related compounds. It has been recommended in the treatment of SCHIZOPHRENIA.. spiperone : An azaspiro compound that is 1,3,8-triazaspiro[4.5]decane which is substituted at positions 1, 4, and 8 by phenyl, oxo, and 4-(p-fluorophenyl)-4-oxobutyl groups, respectively.		1.9610aromatic ketone;
azaspiro compound;
organofluorine compound;
piperidines;
tertiary amino compound		alpha-adrenergic antagonist;
antipsychotic agent;
dopaminergic antagonist;
psychotropic drug;
serotonergic antagonist
dextroamphetamine
Dextroamphetamine: The d-form of AMPHETAMINE. It is a central nervous system stimulant and a sympathomimetic. It has also been used in the treatment of narcolepsy and of attention deficit disorders and hyperactivity in children. Dextroamphetamine has multiple mechanisms of action including blocking uptake of adrenergics and dopamine, stimulating release of monamines, and inhibiting monoamine oxidase. It is also a drug of abuse and a psychotomimetic.. (S)-amphetamine : A 1-phenylpropan-2-amine that has S configuration.		2.36201-phenylpropan-2-amineadrenergic agent;
adrenergic uptake inhibitor;
dopamine uptake inhibitor;
dopaminergic agent;
neurotoxin;
sympathomimetic agent
penfluridol
Penfluridol: One of the long-acting ANTIPSYCHOTIC AGENTS used for maintenance or long-term therapy of SCHIZOPHRENIA and other PSYCHOTIC DISORDERS.		3.7521diarylmethane
butaclamol
(+)-butaclamol : An organic heteropentacyclic compound that is 2,3,4,4a,8,9,13b,14-octahydro-1H-benzo[6,7]cyclohepta[1,2,3-de]pyrido[2,1-a]isoquinoline substituted at position 3 by both hydroxy and tert-butyl groups.		1.9610organic heteropentacyclic compound
butaclamol
[no description available]		1.9510amino alcohol;
organic heteropentacyclic compound;
tertiary alcohol;
tertiary amino compound		dopaminergic antagonist
desipramine hydrochloride
desipramine hydrochloride : The hydrochloride salt of desipramine.		1.9610hydrochloridedrug allergen
thiothixene
[no description available]		1.9510N-methylpiperazineanticoronaviral agent
atropine sulfate
[no description available]		1.9610
clozapine
Clozapine: A tricylic dibenzodiazepine, classified as an atypical antipsychotic agent. It binds several types of central nervous system receptors, and displays a unique pharmacological profile. Clozapine is a serotonin antagonist, with strong binding to 5-HT 2A/2C receptor subtype. It also displays strong affinity to several dopaminergic receptors, but shows only weak antagonism at the dopamine D2 receptor, a receptor commonly thought to modulate neuroleptic activity. Agranulocytosis is a major adverse effect associated with administration of this agent.. clozapine : A benzodiazepine that is 5H-dibenzo[b,e][1,4]diazepine substituted by a chloro group at position 8 and a 4-methylpiperazin-1-yl group at position 11. It is a second generation antipsychotic used in the treatment of psychiatric disorders like schizophrenia.		1.9610benzodiazepine;
N-arylpiperazine;
N-methylpiperazine;
organochlorine compound		adrenergic antagonist;
dopaminergic antagonist;
EC 3.4.21.26 (prolyl oligopeptidase) inhibitor;
environmental contaminant;
GABA antagonist;
histamine antagonist;
muscarinic antagonist;
second generation antipsychotic;
serotonergic antagonist;
xenobiotic
ConditionIndicatedRelationship StrengthStudiesTrials
Acathisia, Drug-Induced
[description not available]		03.3411
Dementia Praecox
[description not available]		04.3122
Schizophrenia
A severe emotional disorder of psychotic depth characteristically marked by a retreat from reality with delusion formation, HALLUCINATIONS, emotional disharmony, and regressive behavior.		09.3122
Basal Ganglia Diseases
Diseases of the BASAL GANGLIA including the PUTAMEN; GLOBUS PALLIDUS; claustrum; AMYGDALA; and CAUDATE NUCLEUS. DYSKINESIAS (most notably involuntary movements and alterations of the rate of movement) represent the primary clinical manifestations of these disorders. Common etiologies include CEREBROVASCULAR DISORDERS; NEURODEGENERATIVE DISEASES; and CRANIOCEREBRAL TRAUMA.		03.3411